Isoray (NYSE:ISR) Coverage Initiated at began coverage on shares of Isoray (NYSE:ISRGet Rating) in a report issued on Monday. The firm set a “sell” rating on the stock.

NYSE ISR opened at $0.27 on Monday. The company has a 50 day simple moving average of $0.32. Isoray has a 12-month low of $0.25 and a 12-month high of $0.94. The company has a market capitalization of $38.68 million, a price-to-earnings ratio of -5.45 and a beta of 1.03.

Isoray Company Profile (Get Rating)

Isoray, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

Recommended Stories

Receive News & Ratings for Isoray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Isoray and related companies with's FREE daily email newsletter.